| Literature DB >> 33644104 |
Jana Maria Nemmer1, Marcus Kuchner1, Angeliki Datsi1,2, Péter Oláh1,3, Valérie Julia4, Ulrike Raap5, Bernhard Homey1.
Abstract
Pruritus represents one of the most common symptoms in dermatology and general medicine. Chronic pruritus severely impairs the quality of life of affected patients. During the last two decades a number of modulators and mediator of pruritus have been identified. Recently, Interleukin (IL)-31 and its receptor complex attracted significant interest, as clinical phase two studies demonstrated therapeutic efficacy of the neutralizing IL-31 receptor A (IL-31RA) antibody nemolizumab in patients suffering from atopic dermatitis or prurigo nodularis. IL-31 has also been shown to play relevant roles in allergic contact dermatitis, urticaria, mastocytosis, allergic rhinitis and asthma. Here, we summarize the current knowledge of the novel cytokine IL-31 and its receptor regarding cellular origin, regulation, signaling pathways and their involvement in biological processes such as pruritus, neuronal growth, inflammation, barrier dysfunction and tissue remodeling.Entities:
Keywords: atopic dematitis; interleukin-31; interleukin-31 receptor; neuroinflammation; pruritus
Year: 2021 PMID: 33644104 PMCID: PMC7902767 DOI: 10.3389/fmed.2021.639097
Source DB: PubMed Journal: Front Med (Lausanne) ISSN: 2296-858X